Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
诺华先期支付20亿美元，拿下Synnovation的下一代PI3Kα抑制剂

Novartis will spend $2 billion upfront to buy a more selective PI3Kα inhibitor, intensifying the competition to develop a new wave of breast cancer drugs with fewer side effects.
诺华将先期支付20亿美元收购一款选择性更高的PI3Kα 抑制剂，加剧了在副作用更少的新一代乳腺癌药物开发领域的竞争。